This inventor holds 3 USPTO granted patents. Top assignee: Kanebo, Limited. Active years: 1984-1989.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Kawanisi, JP (1984)
- Kawanishi, JP (1986)
- Toyonaka, JP (1989)
Company Filing History:
Years Active: 1984-1989
Title: Ryuichi Iemura: Innovator in Pharmaceutical Chemistry
Introduction
Ryuichi Iemura is a notable inventor based in Kawanisi, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that address various medical conditions. With a total of 3 patents to his name, Iemura's work has had a meaningful impact on the industry.
Latest Patents
Iemura's latest patents include a quinazoline derivative that serves as a remedy for cerebral dysfunction. This compound is represented by a specific formula and is noted for its pharmacologically acceptable acid addition salt. Additionally, he has developed novel benzimidazole derivatives that exhibit potent antihistaminic activity with reduced toxicity. These compounds are useful as antihistaminics and are accompanied by processes for their preparation.
Career Highlights
Ryuichi Iemura is currently employed at Kanebo, Limited, where he continues to innovate in the pharmaceutical sector. His work focuses on creating effective and safe medicinal compounds that can improve patient outcomes.
Collaborations
Iemura has collaborated with esteemed colleagues such as Keizo Ito and Tsuneo Kawashima, contributing to a dynamic research environment that fosters innovation.
Conclusion
Ryuichi Iemura's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the field. His work continues to influence the development of effective medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
